Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLC
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Response and progression end points were similar between clinical trial and observational cohorts for non-small cell lung cancer patients. This validates observational data for clinical decision-making and future research.
Area Of Science
- Oncology
- Clinical Trials
- Real-World Evidence
Background
- Response Evaluation Criteria in Solid Tumors (RECIST) are standard in clinical trials but not routine care, limiting their use in observational studies.
- Clinician-anchored response measures are validated but lack comparison with clinical trial data, hindering their application in decision-making.
Purpose Of The Study
- To compare response- and progression-based end points in clinical trial and observational cohorts of non-small cell lung cancer (NSCLC) patients.
- To assess the reliability of observational data for clinical decision-making.
Main Methods
- Retrospective cohort study using data from the IMpower132 trial and an electronic health record (EHR)-derived database.
- Comparison of response rates, duration of response, and progression-free survival between weighted observational and trial cohorts.
Main Results
- Response and progression end points were comparable between the clinical trial and weighted observational cohorts.
- EHR-derived response rates were numerically higher than objective response rates, influenced by the inclusion of patients with no response assessment.
Conclusions
- Response- and progression-based end points are similar between clinical trial and weighted observational cohorts, increasing confidence in observational data reliability.
- Findings support the use of observational data for clinical decision-making and inform future research on EHR-derived response rates.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...